Why the study?
Are plasma soluble endoglin levels an indicator of cardiovascular alterations in hypertensive and diabetic patients?
Are plasma soluble endoglin levels an indicator of cardiovascular alterations in hypertensive and diabetic patients?
Plasma soluble endoglin levels may serve as a biomarker for endothelial dysfunction and cardiovascular damage in patients with hypertension and diabetes.
May support endoglin as a vascular biomarker in hypertension and diabetes; hypothesis-generating and should not yet change practice.
This study shows that endoglin is an indicator of hypertension- and diabetes-associated vascular pathologies as endothelial dysfunction and cardiovascular damage.
No takes yet. Share an insight, caveat, or question.
Blázquez‐Medela et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: